Physician profile
Robert Mark Reed
NPI 1730269911
$8,124.55
in general payments reported to CMS, 2019-2025
40 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $948 · 2020: $835 · 2021: $1,020 · 2022: $1,621 · 2023: $1,414 · 2024: $1,209 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,700.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,294.90 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,020.46 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $923.32 | 2019-2025 | |
| Lilly USA, LLC | $746.44 | 2020-2025 | Jardiance, Emgality, Mounjaro |
| Abbvie INC. | $682.35 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $495.08 | 2019-2022 | |
| Glaxosmithkline, LLC. | $396.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $302.13 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.26 | 2019-2025 | Jardiance, Tradjenta, Ofev |
| Paratek Pharmaceuticals, INC. | $219.32 | 2022-2025 | Nuzyra, Xhance |
| Takeda Pharmaceuticals U.S.A., INC. | $192.50 | 2019-2024 | Trintellix |
| Exact Sciences Corporation | $173.50 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $152.15 | 2022-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $121.64 | 2024-2025 | Gemtesa |
| Dexcom, INC. | $104.29 | 2022-2024 | Dexcom G6 Transmitter |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.